Valuation: Seres Therapeutics, Inc.

Market Cap 68.56M 60.12M 55.41M 51.88M 97.28M 6.47B 99.3M 666M 258M 3.2B 257M 252M 11.08B P/E 2026 *
-0.94x
P/E 2027 * -1.08x
Enterprise Value 68.56M 60.12M 55.41M 51.88M 97.28M 6.47B 99.3M 666M 258M 3.2B 257M 252M 11.08B EV / Sales 2026 *
5.33x
EV / Sales 2027 * 192x
Free-Float
88.22%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day+2.33%
1 week+9.32%
Current month-1.43%
1 month-1.43%
3 months-18.01%
6 months-51.64%
Current year-51.51%
1 week 6.52
Extreme 6.52
7.57
1 month 5.31
Extreme 5.31
7.99
Current year 5.31
Extreme 5.31
16.42
1 year 5.31
Extreme 5.31
29.98
3 years 5.31
Extreme 5.31
105.8
5 years 5.31
Extreme 5.31
501.1
10 years 5.31
Extreme 5.31
770
Manager TitleAgeSince
Chief Executive Officer 70 02/03/2026
Chief Executive Officer 58 01/08/2025
President 51 02/03/2026
Director TitleAgeSince
Chairman 70 02/03/2026
Director/Board Member 50 15/01/2019
Director/Board Member 80 01/04/2015
Date Insider Type Main position Quantity % Market Cap.
05-18Sell

General Counsel

-79 0.0008%
05-18Sell

Chairperson

-77 0.0008%
05-18Sell

Chief Operating Officer

-59 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
+2.90%+9.32%-35.06%-92.31% 68.56M
+0.79%-0.60%+68.41%+123.57% 55.63B
+6.76%+22.83%+91.66%+101.42% 52.25B
+1.42%+2.24%-13.39%-13.82% 23.07B
+1.28%+6.06%+3.92%+414.69% 22.41B
+6.78%+14.47%+40.28%-6.67% 17.32B
+0.97%+3.81%+30.68%-32.21% 15.94B
+0.76%+7.84%+25.64%+192.06% 13.77B
+9.96%+19.81%+157.65%+320.70% 13.47B
+4.21%+4.76%+33.21% - 12.43B
Average +3.54%+6.86%+40.30%+111.94% 22.64B
Weighted average by Cap. +3.51%+7.62%+54.99%+128.43%

Financials

2026 *2027 *
Net sales 12.86M 11.27M 10.39M 9.73M 18.24M 1.21B 18.62M 125M 48.33M 599M 48.28M 47.23M 2.08B 358K 314K 289K 271K 508K 33.77M 518K 3.48M 1.35M 16.69M 1.34M 1.31M 57.87M
Net income -70.97M -62.22M -57.36M -53.7M -101M -6.69B -103M -689M -267M -3.31B -266M -261M -11.47B -99.82M -87.53M -80.68M -75.53M -142M -9.42B -145M -970M -375M -4.65B -375M -367M -16.14B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
29/06/26 $7.220 +1.98% 27,223
26/06/26 $7.080 +3.43% 301,492
25/06/26 $6.845 +0.51% 119,931
24/06/26 $6.810 -3.40% 48,870
23/06/26 $7.050 +6.82% 75,176
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.080USD
Average target price
17.00USD
Spread / Average Target
+140.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock